-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 P0JB3jwtGG3jB8ngYQu5tJh8jTA9Co2rvvk8oDGNY6hK41COsSDhWeqn2PilmcKZ
 O1fxqb55b4YXhGTLySgmYQ==

<SEC-DOCUMENT>0000950123-10-039454.txt : 20101227
<SEC-HEADER>0000950123-10-039454.hdr.sgml : 20101224
<ACCEPTANCE-DATETIME>20100428140533
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-10-039454
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20100428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>corresp</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="FONT-variant: SMALL-CAPS"><B>GeoVax Labs, Inc.</B></FONT><BR>
<B>1900 Lake Park Drive<BR>
Suite&nbsp;380<BR>
Smyrna, Georgia 30080<BR>
(678)&nbsp;384-7220</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">April&nbsp;28, 2010
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Jeffrey P. Riedler<BR>
Assistant Director<BR>
United States Securities and Exchange Commission<BR>
Division of Corporation Finance<BR>
100 F Street, N.E.<BR>
Washington, D.C. 20549

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>RE:</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>GeoVax Labs, Inc.</B><br>
<B>Registration Statement on Form&nbsp;S-1</B><br>
<B>Filed March&nbsp;31, 2010</B><br>
<B>File No.&nbsp;333-165828</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear Mr.&nbsp;Riedler:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This letter is in response to the letter (the &#147;Comment Letter&#148;) dated April&nbsp;14, 2010 from the staff
(the &#147;Staff&#148;) of the United States Securities and Exchange Commission (the &#147;Commission&#148;), with
respect to the GeoVax Labs, Inc. (&#147;GeoVax&#148; or the &#147;Company&#148;) Registration Statement on Form S-1
(File No.&nbsp;333-165828) (the &#147;Registration Statement&#148;). We have set forth below in bold text the
comment contained in the Comment Letter followed by our response.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>General</B></U>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Please revise your disclosure to include a discussion of the allocation of the
purchase price between the company and the selling shareholder for each unit consisting
of a share of common stock being sold by a selling shareholder and a warrant issued by
the company. If the company does not plan to retain any portion of the unit price for
units that include a selling shareholder share of common stock, please include
disclosure of the effect to company shareholders who are not selling shareholders in
the offering.</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>Response </B></U>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We acknowledge the Staff&#146;s comment and plan to amend the Company&#146;s preliminary
prospectus contained in the Registration Statement as set forth on <U>Exhibit&nbsp;A</U>
hereto. Proposed additional language is shown in underlined text, while proposed
deleted language is shown in strikethrough text.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Mr.&nbsp;Jeffrey P. Riedler<BR>
April&nbsp;28, 2010<BR>
Page 2
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We are providing this letter without an accompanying amendment to the Registration Statement based
on our earlier telephone conversation with Ms.&nbsp;Acharya. Upon your approval, the language set forth
in <U>Exhibit&nbsp;A</U> would be included in an amendment to the Registration Statement which we plan
to file in May&nbsp;2010. That amendment will include the Company&#146;s financial statements for the three
months ended March&nbsp;31, 2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In the event the Company requests acceleration of the effective date of the Registration Statement,
it will furnish a letter containing the acknowledgements identified in the third full paragraph on
page two of the Comment Letter.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Please provide our counsel, T. Clark Fitzgerald III, with a copy of any future correspondence. He
can be reached by telephone at (404)&nbsp;879-2455 or email at cfitzgerald@wcsr.com. His facsimile
number is (404)&nbsp;870-4869.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Please do not hesitate to contact the undersigned at (678)&nbsp;384-7224 or mreynolds@geovax.com with
any questions or comments.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Very truly yours,

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Labs, Inc.

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Mark W. Reynolds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Mark W. Reynolds
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chief Financial Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">cc:</TD>
    <TD>&nbsp;</TD>
    <TD>Robert T. McNally, Ph.D.<br>
Nandini Acharya, Esq.</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">
<FONT style="FONT-variant: SMALL-CAPS"><U><B>Exhibit&nbsp;A</B></U></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><I>Preliminary Prospectus Cover Page</I></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The first paragraph will be revised to add the following sentence at the end:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U>All of the warrants included in the units will be issued by us and not the
selling stockholders.</U>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Footnote (2)&nbsp;to the table will be revised as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No units <U>that include shares of our common stock held by selling
stockholders</U> will be sold on behalf of <U>or by</U> the selling
stockholders until after all units offered by the Company are sold. <U>The
selling stockholders will receive all of the proceeds from the sale of units,
if any, that include shares of our common stock held by selling
stockholders</U>.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><I>Page 4, Securities Offered</I></U>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">The discussion will be revised to add the following sentence:<U></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U>All warrants sold will be issued by the Company.</U>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><I>Pages 4 and 16, Use of Proceeds</I></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The last sentence of the &#147;Use of Proceeds&#148; section on page 4 and the first sentence of the last
paragraph on page 16 will both be revised as follows:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">We will not receive any proceeds from the sale of <U>units, if any, that
include</U>&nbsp;shares <U>of our common stock held</U> by the selling stockholders but
we will receive proceeds, if any, from the exercise <U>for cash</U> of warrants
included
<strike>within the</strike> in those units sold
<strike>pursuant to this offering</strike>.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><I>Pages 55-56, Selling Stockholders</I></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We will add the following new information after the footnotes to the table:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U>The selling stockholders will receive the entire price paid by investors for the
units that include shares held by the selling stockholders. From those proceeds,
the selling stockholders will pay the placement agent its 6% commission earned in
connection with the sale of any such units. We will issue the warrants included in
those units and receive proceeds, if any, from the exercise for cash of warrants
included in those units.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U>Emory University and Dr.&nbsp;Robinson sold a portion of their GeoVax shares in 2009,
and each of them, as well as Mr.&nbsp;Hildebrand, indicated an interest in selling
additional shares. We invited each of them to participate in this offering as
selling stockholders in order to encourage them to enter into a lock-up arrangement
satisfactory to the placement agent, to permit an orderly distribution of their
GeoVax shares, and to reduce the perceived market overhang reflected by their
combined holdings.</U>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U>In considering this matter, the Board of Directors recognized that the warrants
to be sold together with shares included as part of the units offered by selling
stockholders have an intrinsic value, which is included in the price per unit to be
paid by investors, but will not be paid to the Company. The Board of Directors also
recognized that all stockholders will experience dilution if the holders of unit
warrants utilize the &#147;cashless exercise&#148; feature. After consideration, the Board of
Directors determined that allowing selling stockholders to receive the implicit
value of the unit warrants was appropriate, given the reasons stated in the
foregoing paragraph, particularly since the selling stockholders may only sell their
shares after the Company sells $30.0&nbsp;million of units. Accordingly, the
arrangements were approved by the Board of Directors, including all of the
independent directors.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U><I>Page 59, Unit Warrants</I></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">The first sentence will be revised as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">In connection with the sale of
<strike>each unit</strike> <U>units by the Company and the
sale of units by the selling stockholders</U> in this offering, we will
issue <U>with each such unit</U> a five-year callable warrant to purchase
up to 0.20 shares of common stock at an exercise price of $&#095;&#095;&#095;&#095; per share,
or 20.0% above the offering price of the units.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
